Drugs that contain Telavancin Hydrochloride

1. Drug name - VIBATIV

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6635618 CUMBERLAND PHARMS Glycopeptide phosphonate derivatives
Sep, 2023

(11 months from now)

US7531623 CUMBERLAND PHARMS Hydrochloride salts of a glycopeptide phosphonate derivative
Jan, 2027

(4 years from now)

CN100532392C CUMBERLAND PHARMS Reductive Alkylation Method
May, 2021

(1 year, 5 months ago)

CN100469788C CUMBERLAND PHARMS Glycopeptide Phosphonic Acid Salt Derivatives
May, 2021

(1 year, 5 months ago)

CN1432023A CUMBERLAND PHARMS Reductive Alkylation Process
May, 2021

(1 year, 5 months ago)

CN1437611A CUMBERLAND PHARMS Glycopeptide Phosphonic Acid Salt Derivatives
May, 2021

(1 year, 5 months ago)

CN1223378C CUMBERLAND PHARMS Pharmaceutical Compositions Containing A Glycopeptide Antibiotic And A Cyclodextrin
May, 2021

(1 year, 5 months ago)

CN1441680A CUMBERLAND PHARMS Pharmaceutical Compositions Containing A Glycopeptide Antibiotic And A Cyclodextrin
May, 2021

(1 year, 5 months ago)

CN1871253A CUMBERLAND PHARMS Hydrochloride Of Glycopeptide Phosphonate Derivatives
Oct, 2024

(2 years from now)

CN100417661C CUMBERLAND PHARMS Hydrochloride Of Glycopeptide Phosphonate Derivatives
Oct, 2024

(2 years from now)

IN200201986P4 CUMBERLAND PHARMS Glycopeptide Phosphonate Derivatives
May, 2021

(1 year, 5 months ago)

IN206947B CUMBERLAND PHARMS Glycopeptide Phosphonate Derivatives
May, 2021

(1 year, 5 months ago)

EP1276759B1 CUMBERLAND PHARMS Reductive Alkylation Process On Glycopeptides
Apr, 2021

(1 year, 5 months ago)

EP1278549B1 CUMBERLAND PHARMS Composition Containing A Cyclodextrin And A Glycopeptide Antibiotic
Apr, 2021

(1 year, 5 months ago)

EP1276759A2 CUMBERLAND PHARMS Reductive Alkylation Process On Glycopeptides
Apr, 2021

(1 year, 5 months ago)

EP1278549A2 CUMBERLAND PHARMS Composition Containing A Cyclodextrin And A Glycopeptide Antibiotic
Apr, 2021

(1 year, 5 months ago)

EP1292611A2 CUMBERLAND PHARMS Glycopeptide Carboxy-Saccharide Derivatives
May, 2021

(1 year, 5 months ago)

EP1292611B1 CUMBERLAND PHARMS Glycopeptide Carboxy-Saccharide Derivatives
May, 2021

(1 year, 5 months ago)

EP1678201A2 CUMBERLAND PHARMS Hydrochloride Salts Of A Glycopeptide Phosphonate Derivative
Oct, 2024

(2 years from now)

EP1678201B1 CUMBERLAND PHARMS Hydrochloride Salts Of A Glycopeptide Phosphonate Derivative
Oct, 2024

(2 years from now)

EP2495251B1 CUMBERLAND PHARMS Hydrochloride Salts Of A Glycopeptide Phosphonate Derivative
Oct, 2024

(2 years from now)

EP2495251A1 CUMBERLAND PHARMS Hydrochloride Salts Of A Glycopeptide Phosphonate Derivative
Oct, 2024

(2 years from now)

EP1292612B1 CUMBERLAND PHARMS Glycopeptide Phosphonate Derivatives
May, 2026

(3 years from now)

EP1292612A2 CUMBERLAND PHARMS Glycopeptide Phosphonate Derivatives
May, 2026

(3 years from now)

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 250MG BASE/VIAL POWDER;INTRAVENOUS Discontinued
EQ 750MG BASE/VIAL POWDER;INTRAVENOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.